ARCHIVES

Hagop Kantarjian: Why Drugs Cost Too Much and How Prices Can be Brought Down

This article is from The Cancer Letter archive.

Vol. 39 No. 22 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

Advisers Discuss What To Do About Physician-Scientists

May 1, 1992

Immunotherapy Shrinks Tumors In Phase I Study at St. Jude

May 30, 2014

340B Drug Discount Program: HRSA Defends Orphan Drug Rule

June 20, 2014

In Brief: Increased Output Can Hold Down High Let Cost, Kligerman says; No More Groups On The Block

March 18, 1977

Progress Measures “Adequate,” Committee Says; Suggestions Include New Death Measure

August 12, 1988

In a letter, ASCO reaffirms its views on oncology consolidation at FDA.

July 9, 2004